Table 3.

SVR12 in cirrhotic and non-cirrhotic hepatitis C virus genotype 1b-infected patients with and without resistance-associated polymorphisms at baseline (immediate treatment arm) n (%)

	Patients with cirrhosis - immediate treatment arm
	With RAPs at baseline				Without RAPs at baseline
	Mainland China	Russia	South Korea	Overall	Mainland China	Russia	South Korea	Overall
Patients with cirrhosis
NS5A-L31M/V	0	0	0	0	15/16 (93.8)	0	2/3 (66.7)	17/19 (89.5)
Y93H	0	0	0	0	15/16 (93.8)	0	2/3 (66.7)	17/19 (89.5)
L31M/V or Y93H	0	0	0	0	15/16 (93.8)	0	2/3 (66.7)	17/19 (89.5)
NS3-D168E	0	0	0	0	15/16 (93.8)	0	2/3 (66.7)	17/19 (89.5)
Patients without cirrhosis
NS5A-L31M/V	1/1 (100)	1/1 (100)	0	2/2 (100)	93/101 (92.1)	21/22 (95.5)	8/10 (80.0)	122/133 (91.7)
Y93H	7/13 (53.8)	0	0/2 (0)	7/15 (46.7)	87/89 (97.8)	22/23 (95.7)	8/8 (100)	117/120 (97.5)
L31M/V or Y93H	8/14 (57.1)	1/1 (100)	0/2 (0)	9/17 (52.9)	86/88 (97.7)	21/22 (95.5)	8/8 (100)	115/118 (97.5)
NS3-D168E	0/1 (0)	0	0	0/1 (0)	94/101 (93.1)	22/23 (95.7)	8/10 (80.0)	124/134 (92.5)

RAP: Resistance-associated polymorphism; SVR12: Sustained virologic response at posttreatment week 12.